TrialScientific reports2022

Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study.

Carolina López-Cano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.